Clinical pharmacist participated in the whole process of combined drug treatment and medication monitoring of a patient with refractory edema secondary to end-stage diabetic kidney disease. By using dapagliflozin combined with sacubitril valsartan and conventional diuretics, the patient's body weight decreased by 16 kg, blood pressure returned to normal, systemic edema subsided and the symptoms of heart failure obviously improved. In this case, clinical pharmacist provided individualized pharmaceutical care and assisted clinicians to make a scientific and reasonable drug therapy, so as to provide a new idea and medication reference for clinical patients to delay the time of renal replacement therapy.

1.Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease[J]. Nat Rev Dis Primers, 2015, 1: 15018. DOI: 10.1038/nrdp.2015.18.

2.GBD chronic Kidney Disease Collaboration. Global, regional, and national burden of motor neuron diseases 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2020, 395(10225): 709-733. DOI: 10.1016/S0140-6736(20)30045-3.

3.Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review[J]. Lancet, 2015, 385(9981): 1975-1982. DOI: 10.1016/S0140-6736(14)61601-9.

4.Meena J, Bagga A. Current perspectives in management of edemain nephrotic syndrome[J]. Indian J Pediatr, 2020, 87(8): 633-640. DOI: 10.1007/s12098-020-03252-9.

5.Ellison DH. Mechanistic insights into loop Diuretic responsiveness in heartfailure[J]. Clin J Am Soc Nephrol, 2019, 14(5): 650-652. DOI: 10.2215/CJN.03590319.

6.Ellison DH. Diuretic drugs and the treatment of edema: from clinic to bench and back again[J]. Am J Kidney Dis, 1994, 23(5): 623-643. DOI: 10.1016/s0272-6386(12)70272-x.

7.Rao VS, Planavsky N, Hanberg JS, et al. Compensatory distal reabsorption drives diuretic resistance in human heart failure[J]. J Am Soc Nephrol, 2017, 28(11): 3414-3424. DOI: 10.1681/ASN.2016111178.

8.朱路, 李华荣. 达格列净: 中国的首个SGLT2抑制剂[J]. 实用药物与临床, 2017, 20(11): 1344-1347. [Zhu L, Li HR. Dapagliflozin: the first sodium-glucose co-transporter 2 inhibitor in China[J]. Practical Pharmacy and Clinical Remedies, 2017, 20(11): 1344-1347.] DOI: 10.14053/j.cnki.ppcr.201711030.

9.庄世虹, 成蓓, 贾海波, 等. 达格列净联合沙库巴曲缬沙坦治疗慢性心力衰竭合并2型糖尿病的疗效和结局[J]. 微循环学杂志, 2021, 31(1): 42-47. [Zhuang SH, Cheng B, Jia HB, et al. Clinical effect and outcome of dapagliflozin combined with sacubitril valsartan in the treatment of chronic heart failure with type 2 diabetes[J]. Chinese Journal of Microcirculation, 2021, 31(1): 42-47.] DOI: 10.3969/j.issn.1005-1740.2021.01.009.

10.Mangiafico S, Costello-Boerrigter LC, Andersen IA, et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics[J]. Eur Heart J, 2013, 34(12): 886-893c. DOI: 10.1093/eurheartj/ehs262.

11.Gardner DG, Chen S, Glenn DJ, et al. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension[J]. Hypertension, 2007, 49(3): 419-426. DOI: 10.1161/01.HYP.0000258532.07418.fa.

12.Sarzani R, Spannella F, Giulietti F, et al. Cardiac natriuretic peptides, hypertension and cardiovascular risk[J]. High Blood Press Cardiovasc Prev, 2017, 24(2): 115-126. DOI: 10.1007/s40292-017-0196-1.

13.Okamoto R, Ali Y, Hashizume R, et al. BNP as a major player in the heart-kidney connection[J]. Int J Mol Sci, 2019, 20(14): 3581-3598. DOI: 10.3390/ijms20143581.

14.Karen MH, Gabriel H, Peter JG, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis[J]. Diabetes Obes Metab, 2018, 20(3): 479-487. DOI: 10.1111/dom.13126.

15.Michelle H, Ryan D, Mariana E, et al. Sodium-glucose cotransporter-2 inhibitors improve heart failure with reduced ejection fraction outcomes by reducing edema and congestion[J]. Diagnostics, 2022, 12(4): 989. DOI: 10.3390/diagnostics12040989.

16.Montalvo-Gordon I, Chi-Cervera LA, Garcia-Tsao G. Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes[J]. Hepatology, 2020, 72(5): 1880-1882. DOI: 10.1002/hep.31270.

17.Ryoko M, Eiryu S, Yumi T, et al. Usefulness of dapagliflozin for nephrotic syndrome secondary to diabetic kidney disease[J]. Internl Med, 2022, 61(24): 3699-3702. DOI: 10.2169/internalmedicine.9121-21.

18.王如欣, 金鑫瑶, 王婷婷, 等. 沙库巴曲缬沙坦对肾功能保护作用的系统评价和meta分析[J]. 中国现代应用药学, 2022, 39(4): 534-541. [Wang RX, Jin XY, Wang TT, et al. Protective effect of sacubitril/valsartan on renal function: systematic review and meta-analysis[J]. Chinese Journal of Modern Applied Pharmacy, 2022, 39(4): 534-541.] DOI: 10.13748/j.cnki.issn1007-7693.2022.04.016.

19.贺红祥, 李贵民, 张文魁. 沙库巴曲缬沙坦联合达格列净治疗2 型糖尿病合并心力衰竭患者的临床对照研究[J]. 实用心脑肺血管病杂志, 2021, 29(6): 99-104. [He HX, Li GM, Zhang WK. Effect of sacubitril/valsartan combined with dapagliflozin in the treatment of patients with heart failure and type 2 diabetes mellitus:a clinical controlled trial[J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 2021, 29(6): 99-104.] DOI: 10.12114/j.issn.1008-5971.2021.00.105.

20.Solomon SD, Jhund PS, Claggett BL, et al. Effect of dapagliflozin in patients with HFrEF treated with sacubitril/valsartan[J]. JACC Heart Fail, 2020, 8(10): 811-818. DOI: 10.1016/j.jchf.2020.04.008.

21.中华医学会糖尿病学分会, 中华医学会内分泌学分会. 中国成人2型糖尿病合并心肾疾病患者降糖药物临床应用专家共识[J]. 中华糖尿病杂志, 2020, 12(6): 369-381. DOI: 10.3760/cma.j.cn115791-20200419-00233.

22.Liew A, Bavanandan S, Prasad N, et al. Asian pacific society of nephrology clinical practice guideline on diabetic kidney disease-an executive summary[J]. Nephrology, 2020, 25(11): 809-817. DOI: 10.1111/nep.13804.

23.KDIGO Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease[J]. Kidney Int, 2020, 98(4S): S1-S115. DOI: 10.1016/j.kint.2020.06.019.

24.Kohan DE, Fioretto P, Johnsson K, et al. The effect of dapagliflozin on renal function in patients with type 2 diabetes[J]. J Nephrol, 2016, 29(3): 391-400. DOI: 10.1007/s40620-016-0261-1.

25.Heerspink HJ, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020, 383(15): 1436-1446. DOI: 10.1056/NEJMoa2024816.

26.Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus[J]. Circulation, 2014, 129(5): 587-597. DOI: 10.1161/CIRCULATIONAHA.113.005081.

27.Anders HJ, Davis JM, Thurau K. Nephron protection in diabetic kidney disease[J]. N Engl J Med, 2016, 375(21): 2096-2098. DOI: 10.1056/NEJMcibr1608564.

28.陈克娜, 谌海兰. 酶法检测肌酐水平降低的秘密: 羟苯磺酸钙的干扰[J]. 国际检验医学杂志, 2021, 42(1): 121-125. [Chen KN, Shen HL. The secret of creatinine decrease by enzyme method: the interference of calcium dobesilate[J]. International Journal of Laboratory Medicine, 2021, 42(1): 121-125.] DOI: 10.3969/j.issn.1673-4130. 2021.01.028.